Shilpa Eyes History At It Nudges Closer To Aflibercept Opportunity In India
Shilpa Biologicals Division Also Has Adalimumab In Its Sights
Amid growing moves in India for local manufacturers to make and supply biosimilars, Shilpa’s biologics division has moved a step closer to becoming the first Indian company to initiate clinical trials for a biosimilar to Regeneron’s Eylea treatment for ophthalmic diseases.
